Press-release for stocks for ONCY

Prices are updated after-hours

symbols : ONCY crawled time : 12:00

save search

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| 1.85% | O: 1.85% H: 0.0% C: 0.0%
biotech fda breast cancer for meeting trial submission

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
Published: 2024-03-05 (Crawled : 12:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| 19.57% | O: 6.52% H: 6.12% C: 5.1%
biotech cancer pancreatic

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
Published: 2023-04-12 (Crawled : 12:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -3.39% | O: -1.63% H: 2.68% C: 0.89%
biotech conference presentation

Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
Published: 2022-08-11 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -15.35% | O: 6.19% H: 0.0% C: -5.8%
biotech results

Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET
Published: 2022-06-28 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| 5.77% | O: -1.92% H: 2.35% C: -2.7%
biotech success cancer pancreatic

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting
Published: 2022-05-04 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -20.86% | O: 2.16% H: 2.11% C: 0.7%
biotech potential cancer breast cancer biomarkers

Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine
Published: 2022-04-14 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -29.49% | O: -3.21% H: 1.99% C: -0.66%
biotech preclinical therapy pre-clinical

Oncolytics Biotech® Letter to Shareholders - Update on Recent Progress
Published: 2022-04-06 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -29.94% | O: -1.27% H: 0.65% C: 0.0%
biotech

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
Published: 2022-03-31 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -30.82% | O: 3.14% H: 0.0% C: -3.66%
biotech gastrointestinal trial positive cancer phase 1

Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort
Published: 2022-03-24 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -30.82% | O: -0.63% H: 4.43% C: 3.8%
biotech chinese treatment trial cancer breast cancer

Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers
Published: 2021-11-03 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -48.6% | O: 1.4% H: 0.49% C: -1.84%
phase 1 test cancer biotech gastrointestinal iot

Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Published: 2021-10-14 (Crawled : 12:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -48.11% | O: 1.42% H: 3.26% C: 1.86%
chinese treatment cancer biotech iot breast cancer trial

Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results
Published: 2021-08-06 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -49.77% | O: -4.11% H: 8.1% C: 6.19%
financial results results biotech iot

Oncolytics Biotech® to Present at the Ladenburg Thalmann Healthcare Conference
Published: 2021-06-30 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -60.57% | O: -0.72% H: 2.53% C: 0.0%
biotech iot conference presentation

Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
Published: 2021-05-07 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -62.33% | O: -0.68% H: 3.79% C: -1.38%
financial results results biotech iot

Oncolytics Biotech® Announces Annual General Meeting
Published: 2021-04-30 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -64.05% | O: -0.65% H: 1.64% C: 0.33%
biotech iot

Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting
Published: 2021-04-12 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology

| -72.57% | O: 1.22% H: 0.27% C: -19.68%
biotech iot therapy preclinical pre-clinical

Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study
Published: 2021-04-12 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K

Health Technology